GSK's Votrient gets first approval in US for kidney cancer
20 October 2009
Malini Guha
GlaxoSmithKline's Votrient (pazopanib) has received its first approval worldwide in the US, for the treatment of advanced renal cell carcinoma (RCC), the main form of kidney cancer.
The oral multi-targeted tyrosine kinase inhibitor, one of GSK's leading anticancers in development for a number...
Please Login to read the full article.